

POSTER PRESENTATION

Open Access

# A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)

Georgina V Long<sup>1\*</sup>, Reinhard Dummer<sup>2</sup>, Antoni Ribas<sup>3</sup>, Igor Puzanov<sup>4</sup>, Olivier Michielin<sup>5</sup>, Ari VanderWalde<sup>6</sup>, Robert HI Andtbacka<sup>7</sup>, Jonathan Cebon<sup>8</sup>, Eugenio Fernandez<sup>9</sup>, Josep Malvehy<sup>10</sup>, Anthony J Olszanski<sup>11</sup>, Thomas F Gajewski<sup>12</sup>, John M Kirkwood<sup>13</sup>, Olga Kuznetsova<sup>14</sup>, Lisa Chen<sup>15</sup>, David R Kaufman<sup>14</sup>, Jeffrey Chou<sup>15</sup>, F Stephen Hodi<sup>16</sup>

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 November 2015

## Background

T-VEC is a herpes simplex virus-1-based oncolytic immunotherapy designed to selectively replicate in tumors, produce GM-CSF, and stimulate antitumor immune responses. OPTiM, a Phase III trial of T-VEC vs GM-CSF in unresectable stage IIIB-IV melanoma, improved the primary endpoint of durable response rate (DRR) in the T-VEC arm (16 vs 2%).[1] Pembrolizumab, a human programmed death receptor-1 (PD-1)-blocking antibody approved for the treatment of advanced metastatic or unresectable melanoma, has demonstrated superiority over the CTLA-4-blocking antibody ipilimumab in patients with stage III or IV melanoma that received no more than one prior line of systemic therapy (PFS HR 0.58, OS HR 0.63-0.69).[2] Combining T-VEC with pembrolizumab may enhance antitumor immune responses vs either therapy alone. Here, we describe a Phase Ib/III study assessing the safety and efficacy of T-VEC + pembrolizumab in unresected stage IIIB-IV melanoma. Twenty-one patients enrolled in Phase Ib December 2014 through March 2015 at 11 institutions in Australia, Spain, Switzerland, and the United States.

## Methods

Primary objective for Phase Ib: assess dose-limiting toxicities of T-VEC + pembrolizumab. Key secondary objectives for Phase Ib: best OR, DRR, duration of response, disease control rate, PFS by investigator using modified immune-related response criteria (irRC), OS, treatment-emergent/related AEs, and potential blood/tumor biomarkers for response/resistance to combination treatment. Key eligibility criteria for Phase Ib: stage IIIB-IV melanoma naïve to systemic treatment (except adjuvant), injectable lesions, ECOG PS 0-1, no active cerebral metastases, no autoimmunity/immunosuppression, and no active herpetic infection. In Phase Ib, T-VEC is injected into cutaneous, subcutaneous, or nodal lesions at up to 4 mL of 10<sup>6</sup> plaque forming units (PFU)/mL day 1, then at up to 4 mL of 10<sup>8</sup> PFU/mL day 22 and Q2W. Pembrolizumab is given 200 mg IV Q2W. Treatment with both therapies continues until (whichever comes first): CR or PD per irRC, intolerance, for up to 2 yrs or, for T-VEC, when there are no longer injectable lesions. The randomized portion of the study comparing T-VEC + pembrolizumab to pembrolizumab alone was originally designed as a Phase II study. An updated Phase III design will be presented.

## Trial registration

ClinicalTrials.gov identifier NCT02263508.

<sup>1</sup>Melanoma Institute Australia and The University of Sydney, Sydney, Australia  
Full list of author information is available at the end of the article

#### Authors' details

<sup>1</sup>Melanoma Institute Australia and The University of Sydney, Sydney, Australia. <sup>2</sup>University Hospital of Zurich, Zurich, Switzerland. <sup>3</sup>University of California at Los Angeles Medical Center, Los Angeles, CA, USA. <sup>4</sup>Vanderbilt University Medical Center, Nashville, TN, USA. <sup>5</sup>Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. <sup>6</sup>The West Clinic, Memphis, TN, USA. <sup>7</sup>University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA. <sup>8</sup>Austin Health, Austin Hospital, Heidelberg, Australia. <sup>9</sup>Hôpitaux Universitaires de Genève, Geneva, Switzerland. <sup>10</sup>Hospital Clinic i Provincial de Barcelona, Barcelona, Spain. <sup>11</sup>Fox Chase Cancer Center, Philadelphia, PA, USA. <sup>12</sup>The University of Chicago Medicine, Chicago, IL, USA. <sup>13</sup>University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. <sup>14</sup>Merck & Co., Inc., Kenilworth, NJ, USA. <sup>15</sup>Amgen Inc., Thousand Oaks, CA, USA. <sup>16</sup>Dana-Farber Cancer Institute, Boston, MA, USA.

Published: 4 November 2015

#### References

1. Andtbacka RH, Kaufman HL, Collichio F, *et al*: **Talimogene Laherparepvec Improves Durable Response Rate in Patients with Advanced Melanoma.** *J Clin Oncol* 2015, doi:10.1200/JCO.2014.58.3377 [epub ahead of print].
2. Robert C, Schachter J, Long GV, *et al*: **Pembrolizumab versus Ipilimumab in Advanced Melanoma.** *N Engl J Med* 2015, **372**:2521-2532.

doi:10.1186/2051-1426-3-S2-P181

**Cite this article as:** Long *et al*: A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265). *Journal for ImmunoTherapy of Cancer* 2015 **3**(Suppl 2):P181.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

